Navigator Medicines
PrivateLast Round
Seed Round
Sep 18, 2026
Est. Valuation
$154M
Total Funding Raised
$100M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Navigator Medicines operates in Healthcare & Life Sciences and is based in Scotch Plains, New Jersey. Its latest recorded funding round was a Series A round in August 2024.
Navigator Medicines is a biotechnology company that develops bispecific antibody therapies for the treatment of complex autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Navigator Medicines Comparables
Compare Navigator Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IMBiologics | 83% | |
| ImageneBio, Inc. | 75% | |
| Amgen | 73% |
For institutional investors. Book with your work email.
Navigator Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Sep 18, 2026 | ||||
| Series A | Aug 27, 2024 |
For institutional investors. Book with your work email.
Navigator Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| Forbion | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
Raised $10M in Seed funding.
- Jun 1, 2026
Grew 23% QoQ, from 22 to 27 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 29, 2026
Navigator Medicines, Inc. presents new data from its bispecific antibody development program at the EADV Congress 2026 in Austria.
- attends_eventSep 29, 2026
Navigator Medicines, Inc. presents emerging data from the NAV-240 and NAV-242 development programs at EADV Congress in 2026.
- is_developingSep 26, 2026
Navigator Medicines, Inc. is developing longer-lasting NAV-242, whose first human study is underway to evaluate safety and pharmacokinetics, with initial results anticipated in late 2026 to support less frequent dosing and improve patient convenience and adherence.
For institutional investors. Book with your work email.
Navigator Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Navigator Medicines's valuation, stock price, and market status.
Is Navigator Medicines a public or private company?
Navigator Medicines is a private company.
What is the current stock price of Navigator Medicines?
Navigator Medicines is a private company, so its shares have no public market price. Caplight tracks Navigator Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Navigator Medicines worth (valuation)?
Navigator Medicines's valuation is estimated at $154.0M based on funding round data.
Can I buy Navigator Medicines stock?
Navigator Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Navigator Medicines's last funding round?
Navigator Medicines's most recent funding round was Seed Round on September 18, 2026.
Who are the main investors in Navigator Medicines?
Key investors in Navigator Medicines include RA Capital Management, Forbion.
Will Navigator Medicines IPO soon?
No public IPO plans have been announced for Navigator Medicines.
How can I track Navigator Medicines secondary market activity?
Caplight tracks bids, offers, and trades in Navigator Medicines's shares on secondary markets.